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Simple Summary: Clinical management of neuroendocrine neoplasms (NEN), especially of those low
in target molecules such as somatostatin receptors, may benefit from the discovery of novel targets.
This study identified and confirmed angiotensin II (ATII) as a strong activator of signaling in NEN
cells and its cognate receptor AGTR1 as overexpressed in human small intestinal NEN. NEN cells
with high AGTR1 expression exhibited cellular activation and secretion upon stimulation with ATII.
AGTR1 ligand saralasin coupled to a fluorescent dye demonstrated tumor accumulation in an animal
model of NEN. This proof of concept establishes AGTR1 as a novel target in NEN, paving the way for
its potential use in diagnostic PET imaging and radioligand therapy.
Abstract: This study identified and confirmed angiotensin II (ATII) as a strong activator of signaling
in neuroendocrine neoplasm (NEN) cells. Expression analyses of the ATII receptor type 1 (AGTR1)
revealed an upregulation of mRNA levels (RT-qPCR) and radioligand binding (autoradiography) in
small-intestinal (n = 71) NEN tissues compared to controls (n = 25). NEN cells with high AGTR1
expression exhibited concentration-dependent calcium mobilization and chromogranin A secretion
upon stimulation with ATII, blocked by AGTR1 antagonism and Gαq inhibition. ATII also stimulated
serotonin secretion from BON cells. AGTR1 ligand saralasin was coupled to a near-infrared fluorescent
(NIRF) dye and tested for its biodistribution in a nude mouse model bearing AGTR1-positive BON
and negative QGP-1 xenograft tumors. NIRF imaging showed significantly higher uptake in BON
tumors. This proof of concept establishes AGTR1 as a novel target in NEN, paving the way for
translational chelator-based probes for diagnostic PET imaging and radioligand therapy.
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1. Introduction
Neuroendocrine neoplasms (NENs) represent a heterogeneous group of neoplasms with a
moderate but steadily increasing annual age-adjusted incidence of approximately 7/100,000 for
the USA in 2012 [1]. Most NENs grow rather slowly and may develop into a more aggressive
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phenotype while being undetected. Somatostatin analogs (SSAs) such as octreotide are used as
antisecretory and antiproliferative medication. Apart from direct pharmacological intervention, SSTR
overexpression in NENs has also been utilized for targeted molecular imaging and peptide receptor
radiotherapy (PRRT) [2–5]. However, up to 30% of patients do not fully benefit from these approaches.
While some tumors lack SSTR expression or downregulate expression upon treatment, others exhibit
an inhomogeneous receptor distribution resulting in a residual tumor mass after treatment and
subsequent resistance to SSAs [6,7]. Other possible resistance mechanisms include the following:
receptor desensitization, downregulation or loss-of-function as well as altered signaling pathways [7,8].
Most patients develop SSA resistance within weeks to months of treatment, with recurrent symptoms
and tumor growth [9].
To identify alternative target receptors at the cell surface of NENs, this study used high-throughput
screening technology to detect G protein-coupled receptor (GPCR) activation in human NEN cells.
The screening revealed a clear response towards angiotensin II (ATII). Therefore, this study went on
to assess the potential of AGTR1 as a novel target in NEN. Study objectives were to validate AGTR1
mRNA expression and ligand binding in human NEN tissue, to investigate the biological effects of
ATII in human cell models, and to evaluate the suitability of AGTR1 as a target for tumor diagnosis in
a mouse xenograft model.
2. Results
A 998-compound chemical library mainly consisting of peptide receptor ligands (Table S1) was
applied in a primary screening in the NEN cell line BON. Both a label-free dynamic mass redistribution
(DMR) as well as an intracellular calcium mobilization assay were employed in 384-well format
(Figure 1A–C). A total of 89 hits were detected (8.9%), which were assayed again in BON cells
in a 96-well format (Figure 1D,E). Thirty primary hits, including structurally related compounds,
were confirmed in 96-well format in the DMR assay, and 19 hits in the calcium assay, with 11 compounds
confirmed in both assays (Table S2). Angiotensin II (ATII) appeared consistently as a strong activator
of intracellular signaling in BON cells. This was subsequently validated in three functional assays:
DMR, calcium and impedance. Quantitative analysis showed a half maximal effective concentration
(EC50) for ATII of 0.88 ± 0.28 nM, 4.9 ± 5.2 nM and 0.45 ± 0.03 nM in DMR, calcium and impedance,
respectively (Figure 1F–H).
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Figure 1. Identification and confirmation of ATII-induced signaling in neuroendocrine neoplasm 
(NEN) cells. (A) Schematic workflow of the screening and hit confirmation approach. A 998-
compound library of peptides and small molecules was used in the primary screening on 
neuroendocrine BON cells, applying both dynamic mass redistribution (DMR) and calcium 
mobilization assay in the 384-well format, followed by hit confirmation using the calcium assay (96-
well format). Finally, DMR, calcium and impedance assays were used to determine quantitative 
pharmacological data. (B) Pseudocolor representation of the screening result from one DMR assay 
plate. Duplicates are interspaced by one well, penultimate row contains positive and negative 
controls. (C) Representative results from calcium assay, plate layout as in (B). (D) Plate view of the 
hit confirmation calcium assay with fluorescence intensity traces for each well. (E) Plate layout with 
ligands used for hit confirmation, plate as in (D). (F–H) Concentration–response curve for angiotensin 
II in BON cells measured by DMR assay (F), calcium mobilization (G) and impedance (H). 
Endogenous expression of the ATII receptor AGTR1 was assessed in five NEN cell lines by 
RT-qPCR and compared to mRNA levels of 23 other tumor and non-tumor cell lines (Figure 2A). 
NEN cell lines BON and H727 exhibited the highest mRNA levels of all tested, indicating an AGTR1 
overexpression in NEN. The NEN cell line QGP-1 showed an at least 1000-fold lower AGTR1 mRNA 
expression, while LCC-18 and UMC-11 had intermediate expression levels. Pancreatic (n = 42) and 
small-intestinal (n = 71) tumor tissues of NEN patients were analyzed for their AGTR1 mRNA levels. 
To allow a direct comparison with their organs of origin, normal control tissues (n = 25) were also 
included. Small-intestinal NEN (siNEN) demonstrated significantly (p < 0.001) increased AGTR1 
transcript levels, with an overall 2.8-fold higher median value in comparison to healthy control 
tissues, whereas pancreatic tissues showed no significant difference (Figure 2B). Taking the median 
value of the siNEN samples as a cut-off, 50% of tumor samples yet only 7.7% of controls were above 
that value. When all NENs were compared to all controls, differences were also significant (3.6-fold 
higher median, p < 0.01). No correlation of AGTR1 mRNA levels with stage, grade or Ki67 value were 
found (see Figure S1 for correlation analysis with Ki67). To allow a direct comparison, AGTR1 mRNA 
levels in NEN cell lines, normal controls and NEN tumor tissue were analyzed and plotted. Normal 
pancreas, pancreatic islets and small intestine showed similar mRNA levels. Higher levels in pNEN 
and siNEN samples matched well those of NEN cell lines BON and H727, while the other NEN cell 
lines were found to have lower mRNA levels (Figure 2C). The same clinical samples were also 
analyzed for expression of the established NEN target SSTR2, which was found to be significantly 
upregulated in both pancreatic and siNEN tissues, as expected. The ratio of NEN to control median 
values was higher for SSTR2 (8.5 versus 3.6 for AGTR1). However, AGTR1 was detected at an 
approximately 10-fold higher expression level than SSTR2. Correlation analysis confirmed a 
significant positive correlation between AGTR1 and SSTR2 expression for small-intestinal NENs 
(Pearson r = 0.37, p < 0.001, r² = 0.14), whereas no significant correlation was found for pancreatic 
samples (r = −0.09) (Figure 2D,E). 
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i r 1. Identification and confirmation of ATII-induced signaling in neuroendocri e neoplasm (NEN)
cells. (A) Schematic workflo f the screening and hit confirmation approach. A 998-compound
library of peptides and small molecules was used in the primary screening on neuroendocri e BON
cells, applying both dynamic mass redistribution (DMR) and calcium mobilization assay in the
384-well format, followed by hit confirmation using the calciu assay (96-well format). Finally,
DMR, calcium and impedance assays were used to determine quantitative phar acological data.
(B) Pseudocolor representation of the screening result from one DMR assay plate. Duplicates are
interspaced by one well, penultimate row contains positive and negative controls. (C) Representative
results from calcium assay, plate layout as in (B). (D) Plate view of the hit confirmation calcium assay
with fluorescence intensity traces for each well. (E) Plate layout with ligands used for hit confirmation,
plate as in (D). (F–H) Concentration–response curve for angiotensin II in BON cells measured by DMR
assay (F), calcium mobilization (G) and impedance (H).
Endogenous expression of the ATII receptor AGTR1 was assessed in five NEN cell lines by
RT-qPCR and compared to mRNA levels of 23 other tumor and non-tumor cell lines (Figure 2A).
NEN cell lines BON and H727 exhibited the highest mRNA levels of all tested, indicating an AGTR1
overexpression in NEN. The NEN cell line QGP-1 showed an at least 1000-fold lower AGTR1 mRNA
expression, while LCC-18 and UMC-11 had intermediate expression levels. Pancreatic (n = 42) and
small-intestinal (n = 71) tumor tissues of NEN patients were analyzed for their AGTR1 mRNA levels.
To allow a direct comparison with their organs of origin, normal control tissues (n = 25) were also
included. Small-intestinal NEN (siNEN) demonstrated significantly (p < 0.001) increased AGTR1
transcript levels, with an overall 2.8-fold higher median value in comparison to healthy control tissues,
whereas pancreatic tissues showed no significant difference (Figure 2B). Taking the median value
of the siNEN samples as a cut-off, 50% of tumor samples yet only 7.7% of controls were above that
value. When all NENs were compared to all controls, differences were also significant (3.6-fold higher
median, p < 0.01). No correlation of AGTR1 mRNA levels with stage, grade or Ki67 value were found
(see Figure S1 for correlation analysis with Ki67). To allow a direct comparison, AGTR1 mRNA levels
in NEN cell lines, normal controls and NEN tumor tissue were analyzed and plotted. Normal pancreas,
pancreatic islets and small intestine showed similar mRNA levels. Higher levels in pNEN and siNEN
samples matched well those of NEN cell lines BON and H727, while the other NEN cell lines were
found to have lower mRNA levels (Figure 2C). The same clinical samples were also analyzed for
expression of the established NEN target SSTR2, which was found to be significantly upregulated in
both pancreatic and siNEN tissues, as expected. The ratio of NEN to control median values was higher
for SSTR2 (8.5 versus 3.6 for AGTR1). However, AGTR1 was detected at an approximately 10-fold
higher expression level than SSTR2. Correlation analysis confirmed a significant positive correlation
between AGTR1 and SSTR2 expression for small-intestinal NENs (Pearson r = 0.37, p < 0.001, r2 = 0.14),
whereas no significant correlation was found for pancreatic samples (r = −0.09) (Figure 2D,E).
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Figure 2. Increased AGTR1 gene expression in pancreatic and small intestinal NEN tissue and two 
NEN cell lines. (A) AGTR1 expression was measured as mRNA levels by RT-qPCR in 28 cell lines of 
different origin. Values were normalized on UBC, HPRT1 and GAPDH. Bars show mean ± SD (n = 2, 
different passages). (B) AGTR1 mRNA levels determined by RT-qPCR in pancreatic (n = 42) and small 
intestinal (n = 71) NEN tissues in comparison to pancreatic (n = 12) and small intestinal (n = 13) control 
tissues. Values were normalized on ALG9, UBC and HPRT1 and compared to SSTR2 gene expression 
in the same samples. Bars represent median. Evaluated with unpaired two-tailed Student’s t-test, ** p 
< 0.01, *** p < 0.001, **** p < 0.0001. (C) Direct comparison of AGTR1 expression in NEN cell lines (dark 
grey bars), normal tissues (pancreatic islets, pancreas, small intestine; light grey bars) and NEN tissue 
(black bars). (D,E) Scatter plots showing the correlation of AGTR1 with SSTR2 gene expression in 
pancreatic (pNEN) and small intestinal (siNEN) tumor tissues. 
To verify AGTR1 gene expression employing an alternative methodology, ten normal control 
samples from pancreas and small intestine as well as eight pancreatic and nine small-intestinal NEN 
samples were selected for the determination of receptor binding sites by in vitro receptor 
autoradiography (patient characteristics: Table S3). To this end, the natural receptor ligand ATII was 
radioactively labeled with iodine-125 (125I–ATII) and purified by high-performance liquid 
chromatography (HPLC) (Figure S2). Consecutive cryosections of each tissue were incubated with 
the radioligand in the absence or presence of an excess of non-labeled ATII. To distinguish between 
receptor subtypes, additional tissue sections were incubated with radioligand and AGTR1-specific 
antagonist valsartan or AGTR2-specific antagonist PD123319 (Figure 3A, Figures S4 and S5). 
Pancreatic NEN tissues showed a rather weak overall binding of 125I–ATII. Nevertheless, in tissues #4 
(Figure 3A), #1, #6 and #8 (Figure S4), it could be clearly displaced by ATII and valsartan, but not by 
PD123319, indicating dominant AGTR1 expression. Small-intestinal NENs, on the other hand, 
demonstrated a strong binding in more than half of the samples (#9 to #13) (Figure 3A, Figure S4). 
This proved to be AGTR1-specific binding as it could only be displaced by valsartan. PD123319 was 
unable to compete with the radioligand. In addition, pancreatic and small-intestinal control tissues 
were included in the analysis (Figure 3A, Figure S5). Interestingly, a number of pancreatic samples 
exhibited strong radioligand binding. In comparison to pancreatic NEN samples, signals in normal 
Figure 2. Increased AGTR1 gene expression in pancreatic and small intestinal NEN tissue and two
NEN cell lines. (A) expr ssion was measured as mRNA levels by RT-qPCR in 28 c ll lines of
different origin. Values wer normalized on UBC, HPRT1 and GAPDH. Bars show mean ± SD (n = 2,
ff passages). (B) AGTR1 mRNA levels determined by RT-qPCR in p ncreatic (n = 42) and small
intestinal (n = 71) NEN tissues in comparison to pancreatic (n = 12) and small intestinal (n = 13) contro
tissues. Values were normalized on ALG9, UBC and HPRT1 and compared to SSTR2 gene expression
in th same sampl s. Bars represent median. Evaluated with unpaired two-tailed Stud nt’s t-test,
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(dark grey bars), normal tissues (pancreatic islets, pancreas, small intestine; light grey bars) and NEN
tissue (black bars). (D,E) Scatter plots showing th correl tio of AGTR1 with SSTR2 gene expression
in pancreatic (pNEN) and small intesti al (siNEN) tumor tissues.
To verify AGTR1 gene expression employing an alternative methodology, ten normal control
samples from pancreas and small intestine as well as eight pancreatic and nine small-intestinal
NEN samples were selected for the determination of receptor binding sites by in vitro receptor
autoradiography (patient characteristics: Table S3). To this end, the natural receptor ligand ATII
was radioactively labeled with iodine-125 (125I–ATII) and purified by high-performance liquid
chromatography (HPLC) (Figure S2). Consecutive cryosections of each tissue were incubated with
the radioligand in the absence or presence of an excess of non-labeled ATII. To distinguish between
receptor subtypes, additional tissue sections were incubated with radioligand and AGTR1-specific
antagonist valsartan or AGTR2-specific antagonist PD123319 (Figure 3A, Figures S4 and S5). Pancreatic
NEN tissues showed a rather weak overall binding of 125I–ATII. Nevertheless, in tissues #4 (Figure 3A),
#1, #6 and #8 (Figure S4), it could be clearly displaced by ATII and valsartan, but not by PD123319,
indicating dominant AGTR1 expression. Small-intestinal NENs, on the other hand, demonstrated a
strong binding in more than half of the samples (#9 to #13) (Figure 3A, Figure S4). This proved to be
AGTR1-specific binding as it could only be displaced by valsartan. PD123319 was unable to compete
with the radioligand. In addition, pancreatic and small-intestinal control tissues were included in
the analysis (Figure 3A, Figure S5). Interestingly, a number of pancreatic samples exhibited strong
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radioligand binding. In comparison to pancreatic NEN samples, signals in normal pancreas were
displaced solely by PD123319, indicating a specific expression of AGTR2. Small-intestinal control
samples showed no binding at all (#23, #25) or non-specific binding (#24, #26, #27) (Figure S5).
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Digitized autoradiograms were quantified by calculating the ratios of total binding to non-
specific binding in the presence of excess ATII, valsartan or PD123319 (Figure 3B–D). The higher a 
ratio, the higher the expression of the respective receptor subtype. Indeed, valsartan-related ratios 
were increased up to 5-fold in NEN tissues, especially in small-intestinal NENs, when compared to 
their respective control tissues. This confirmed a specific AGTR1 expression (Figure 3C). To verify 
these findings using a different quantitative analysis, tissues were wiped off the slides after 
Figure 3. In vitro receptor autoradiography confirms increased AGTR1, not AGTR2 expression in
pancreatic and small intestinal NENs. From all samples that were analyzed by RT-qPCR, 10 control and
17 NEN sample were us d for autoradiographic evaluation of rec ptor expression. (A) Hematoxylin
and eosin (H&E) staining and autoradiog ams f representative pancreatic (pNEN) and small inte tinal
(siNEN) tumors as well as of pancreatic, small intestinal (SI) and liver control tissues. For each tissue,
consecutive cryosections were either incubated with iodine-125 labeled angiotensin II alone (125I–ATII,
total binding) or in the presence of additional 1 µM unlabeled ATII, AGTR1 antagonist valsartan
or AGTR2 antagonist PD123319 (non-specific binding). (B–D) For all autoradiograms, mean signal
intensities per area were calculated and are shown as ratios of total to non-specific binding for ATII (B),
valsartan (C) and PD123319 (D). (E) Scatter plot showing the correlation of AGTR1 gene expression
(x-axis, RT-qPCR) with receptor protein expression (y-axis, autoradiography). (F) For the analyzed NEN
tissue samples, AGTR1 gene expression levels were compared to their SSTR2 expression, as measured
with RT-qPCR (see Figure 2).
Digitiz au oradiograms w re quantifi d by calculating the ratios of total binding to non-specific
binding in the presence of excess ATII, valsartan or PD123319 (Figure 3B–D). The higher a ratio,
the higher the expression of the respective receptor subtype. I deed, v lsartan-related ratios were
increased up to 5-fold in NEN tissues, especially in small-intestinal NENs, when compared to their
respective cont ol tissues. This c nfirmed a specific AGTR1 expression (Figure 3C). To verify these
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findings using a different quantitative analysis, tissues were wiped off the slides after radioligand
incubation and measured by a gamma counter. This alternative quantification yielded similar results
(Figure S3). As depicted in Figure 3F, mRNA levels correlated well with binding levels for most
tissues (Pearson r = 0.43, p ≤ 0.01, r2 = 0.184). While controls showed low mRNA and low binding
levels, NENs in general had relatively high mRNA and binding levels. A similar correlation using
the alternative quantification confirmed this result (Figure S3B). Furthermore, AGTR1 mRNA levels
of the samples analyzed by autoradiography were individually compared to those of SSTR2 mRNA
(Figure 3E. All these NEN tissues showed higher AGTR1 than SSTR2 mRNA levels.
After target validation in patient tissues, receptor-positive cell lines BON and H727 were further
evaluated as models for AGTR1 expression and function in NEN. Confirming gene expression data
(Figure 2A), both cell lines exhibited significant specific binding of 125I–ATII that could be displaced
by unlabeled ATII, whereas the other NEN cell lines QGP-1, LCC-18 and UMC-1 demonstrated only
background levels of radioligand binding (Figure 4A). Saturation radioligand binding experiments
determined Kd values of 0.6 nM for BON and 1.2 nM for H727 (Figure 4B). In contrast, the cell lines
differed in their receptor density as indicated by the Bmax value, which was 3-fold higher for BON
(~50,000 binding sites/cell) in comparison to H727 cells (~16,000 binding sites/cell). As depicted
in Figure 4C, binding of 125I–ATII to BON and H727 cells could be displaced in a dose-dependent
fashion by ATII and the AGTR1-specific antagonist valsartan, but not by the AGTR2-specific antagonist
PD123319. Calculated Ki values reflect the expected high affinity of ATII for AGTR1 (BON: 0.1 nM,
H727: 0.2 nM). Ki values of valsartan were slightly higher, but still in the low nanomolar range
(BON: 4.3 nM, H727: 9.4 nM). It was further shown that both cell lines retained AGTR1 expression and
radioligand binding capacity during xenotransplantation and tumor growth in nude mice, as analyzed
by receptor autoradiography (Figure 4D).
Cellular signaling, secretion and cell viability of BON and H727 cells were evaluated upon
receptor stimulation or inhibition. Receptor activation was studied by an intracellular calcium
mobilization assay. While concentration-dependent response curves could be obtained for BON and
H727, demonstrating functionally active receptor in these cells, QGP-1 and LCC-18 showed no calcium
mobilization (Figure 5A). Furthermore, valsartan was able to significantly diminish the induced signal,
while PD123319 did not influence receptor activation, indicating selective AGTR1, not AGTR2 signaling
(Figure 5A). Valsartan inhibited ATII-mediated calcium mobilization in a concentration-dependent
manner (Figure 5B). Gαq inhibition completely abolished the signal, whereas β-arrestin blockage did
not modulate the effect. Inhibition of ERK or AKT also did not change the calcium response in BON
cells (Figure 5B).
BON cell supernatants were tested for their chromogranin A (CgA) content after ATII treatment.
Interestingly, CgA secretion in these cells was stimulated in a concentration-dependent manner.
CgA secretion was diminished after preincubation with AGTR1 antagonist valsartan (Figure 5C).
Moreover, ATII treatment stimulated the release of serotonin (5HT) to the cell supernatant,
while application of the receptor blockers valsartan and azilsartan did not modify basal 5HT secretion
(Figure 5D). When investigating metabolic activity as a readout for cell growth and viability, no change
could be detected after 96 hours of treatment with different concentrations of agonist (ATII) or antagonist
(valsartan) (Figure 5E).
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Cellular signaling, secretion and cell viability of BON and H727 cells were evaluated upon 
receptor stimulation or inhibition. Receptor activation was studied by an intracellular calcium 
mobilization assay. While concentration-dependent response curves could be obtained for BON and 
H727, demonstrating functionally active receptor in these cells, QGP-1 and LCC-18 showed no 
calcium mobilization (Figure 5A). Furthermore, valsartan was able to significantly diminish the 
induced signal, while PD123319 did not influence receptor activation, indicating selective AGTR1, 
not AGTR2 signaling (Figure 5A). Valsartan inhibited ATII-mediated calcium mobilization in a 
concentration-dependent manner (Figure 5B). Gαq inhibition completely abolished the signal, 
whereas β-arrestin blockage did not modulate the effect. Inhibition of ERK or AKT also did not 
change the calcium response in BON cells (Figure 5B). 
Figure 4. NEN cell lines BON and H727 fi expres AGTR1, not AGTR2. (A) NEN cell lines
were incubated with 125I–ATII alone (total bin i g) or i the presence of ad itional 1 µM unlabeled
ATII (non-specific binding). Data represent mean ± S.E. . (n = 3). Evaluated with two-way ANOVA,
**** p < 0.0001. (B,C) Saturation (B) and competition (C) binding assays were performed for BON
and H727 cells. Data represent mean ± S.E.M. (n = 3). (B) Cells were incubated with increasing
concentrations of 125I–ATII in absence (total binding) or presence of 1 µM unlabeled ATII (non-specific
binding). Specific binding was calculated by subtraction of non-specific from total binding. (C) Cells
were incubated with 125I–ATII and increasing concentrations of either unlabeled ATII, valsartan (AGTR1
antagonist) or PD123319 (AGTR2 antagonist). (D) Autoradiograms of BON and H727 xenografts
showing total (125I–ATII) or non-specific binding in the presence of 1 µM ATII, valsartan or PD123319.
cpm, counts per minute.
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Figure 5. Calcium signaling, chromogranin A secretion and viability of NEN cell lines after stimulation
of AGTR1. (A) NEN cell lines were preloaded with the calcium indicator fluo-4, and its increasing
fluorescence after application of ATII was recorded (left). BON and H727 were additionally pretreated
with 1 µM valsartan or PD123318 for 15 min before ATII stimulation (right). Data show mean ± S.E.M.
(n ≥ 3). Evaluated with two-way ANOVA, **** p < 0.0001. (B) BON and H727 cells were preloaded
with the calcium indicator fluo-4 and preincubated with either valsartan, Gαq blocker UBO-QIC,
β-arrestin blocker barbadin or inhibitors for ERK or AKT (BON cells) for 15–30 min. Fluorescence
intensity after application of ATII was recorded. Data show mean ± S.E.M. (n ≥ 3). (C) BON cells were
either treated with increasing concentrations of ATII (main figure) or pretreated for 15 min with 10 µM
valsartan or PD123318 before application of 100 nM ATII (inset). Chromogranin A (CgA) content of
the supernatants was measured after 6 h (left) or 24 h (right), respectively. Data show mean ± S.E.M.
(n ≥ 2). Values were normalized on untreated controls. (D) BON cells were treated with either 1 µM
ATII, valsartan or azilsartan. Serotonin (5HT) content of the supernatants was determined after 6 h.
Values were normalized on untreated controls. Data show mean ± S.E.M. (n = 3). (E) BON and H727
cells were incubated with increasing concentrations of angiotensin II or valsartan for 96 h and analyzed
for their metabolic activity by addition of AlamarBlue. Data show mean ± S.E.M. (n = 4).
Finally, the capacity of AGTR1 to act as a target for in vivo molecular diagnostic imaging was
assessed. To this end, the partial AGTR1/2 agonist saralasin was coupled via a 4,7,10-trioxatridecan-
succinamic acid (TTDS) linker to the near-infrared fluorescent dye indotricarbocyanine (ITCC).
Radioligand binding assays with 125I–ATII were conducted to determine the affinity of the fluorescent
probe in vitro (Figure 6A). In AGTR1-positive BON cells, the radioligand could be displaced by
unlabeled ATII confirming its high affinity (Ki = 0.1 nM) as determined before (Figure 4C). The binding
curve of saralasin–ITCC was shifted to the right, indicating lower binding affinity at a Ki value
of 246.5 nM. In contrast, receptor negative QGP-1 cells did not show binding at all. For in vivo
imaging, immunodeficient nude mice were subcutaneously inoculated with BON cells on the right
and QGP-1 cells on the left shoulder. Near-infrared fluorescent imaging of live animals was performed
after sufficient tumor growth, and the ITCC-labeled probe was tested in four different animals.
Biodistribution kinetics of saralasin–ITCC of one animal after intravenous application is shown in
Figure 6B. Visual evaluation of the images indicated a selective accumulation of saralasin–ITCC in
AGTR1-positive BON tumors, which proved to be statistically significant at three, four, five and
six hours post-injection (Figure 6C). Tumor-to-background ratios were 2- to 3-fold higher when
compared to the image acquired prior to injection. Low non-significant uptake was detected in receptor
negative QGP-1 tumors. Ex vivo organ imaging 6 hours after injection confirmed the specificity of
saralasin–ITCC for receptor-positive BON tumors as well as an accumulation in kidneys and liver
(Figure 6D). Similarly, AGTR1 small molecule antagonist valsartan was labeled with ITCC via a
1,3-diamino propane linker and used for the same type of imaging. Although the affinity of this
fluorescent ligand conjugate (IC50 = 18.6 nM) was higher than for saralasin–ITCC, the accumulation of
valsartan–ITCC in AGTR1-positive NEN xenograft tumors proved to be less pronounced (Figure S6).
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Figure 6. In vivo near-infrared fluorescent (NIRF) imaging with AGTR1-targeting saralasin–ITCC.
(A) AGTR1-positive BON and AGTR1-negative QGP-1 cells were incubated with 125I–ATII and
increasing concentrations of unlabeled ATII or saralasin–ITCC. Data show mean ± S.E.M. for BON
(n = 3–4) or mean ± S.D. for QGP-1 (n = 1). (B) Biodistribution of 1 nmol i.v. saralasin–ITCC in a mouse
model subcutaneously injected with BON (right shoulder) and QGP-1 cells (left shoulder). Images were
acquired at the indicated time points before or after injection and are displayed with an equally adjusted
gain for either dorsal or ventral signals. (C) Signals from in vivo NIRF imaging were quantified by
calculating the ratio of signal (tumor) to background (neck) for saralasin–ITCC. Bars represent mean
± S.E.M. of four different animals. Evaluated with matched two-way ANOVA and Bonferroni post
hoc test, * p < 0.05, **** p < 0.0001. (D) Ex vivo NIRF imaging of tumors and organs 6 h after injection,
exemplary images from one animal. cpm, counts per minute; ITCC, indotricarbocyanine.
3. Discussion
In search of alternative targets that may be used for diagnosis and treatment of NENs, this study
employed cell-based screening in human NEN cells using a compound library of 998 peptides and
small molecules, yielding 38 confirmed hits, including ATII and a number of other GPCR ligands.
These results stress the validity of activity-based screening approaches (reverse genetics) to identify
new targets in oncology. In a comprehensive analysis of AGTR1 expression in 123 NEN patient and
25 control samples, this study demonstrated an upregulation of AGTR1 in small-intestinal NENs.
While absolute expression in cancer tissue may be the most important criterion for judging the
usefulness of a theranostic target, comparison with expression in normal tissues can be indicative of
potential background signals in the organs of origin (pancreas, small intestine). Correlation analyses
revealed a positive correlation between AGTR1 and SSTR2 expression in these samples. However,
a subset of patients with low SSTR2 and high AGTR1 expression could benefit from tumor targeting
approaches based on AGTR1 ligands. Data for the other SSTR family members have not been obtained.
However, as SSTR2 is dominant for targeting in terms of both tumor expression as well as somatostatin
analogue affinity, the contribution of other SSTRs to the imaging success would probably be limited.
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While mRNA expression data provide important insights into differentially regulated transcript
levels, the existence of sufficient receptor protein at the cell surface is a prerequisite for molecular
targeting. In a previous study, AGTR1 protein expression in 44 pancreatic NENs had been evaluated by
immunohistochemistry [10]. This paper observed an expression in 80% of the patients. However, the
antibody employed in this paper was demonstrated to be non-specific in two studies [11,12]. Due to the
lack of validated AGTR1 antibodies, in the current study, protein expression was indirectly evaluated
by receptor autoradiography as an alternative method. Quantification revealed an up to 5-fold higher
binding of AGTR1 in particular in small-intestinal NENs. This was found to correlate well with mRNA
expression for most samples.
In a panel of 28 cell lines tested for AGTR1 expression, the two cell lines with the highest AGTR1
mRNA expression were of NEN origin, whereas only one colon and one lung cancer cell line reached
similarly high values. This may indicate that AGTR1 overexpression is not a general phenomenon in
tumors, but may be of particular relevance to NENs. Specific AGTR1 expression in these cell lines was
independently confirmed by radioactive binding assays and autoradiography.
Several studies showed that ATII facilitates cell proliferation in various human cancer cell lines,
including breast [13], prostate [14] and pancreatic cells [15]. The proposed proliferative effect, however,
could not be confirmed in this study, as metabolic activity was not affected. Likewise, treatment
with the AGTR1 antagonist valsartan revealed no inhibition of cell growth. BON and H727 might
release ATII, leading to autocrine signaling and enhanced cell proliferation, making externally added
treatment negligible. This would be in line with a previous study in which treatment with the ACE
inhibitor enalapril, and thereby inhibition of ATII production, resulted in decreased BON cell growth
in vitro and in vivo [10]. Similarly, the effect of applied antagonists might be impaired as they have to
compete with autocrine ATII binding for the receptors [16]. Furthermore, ATII mediates its proliferative
signaling not only by direct stimulation of tumor cells, but also indirectly affects stromal and vascular
cells [17], which are not present in most monolayer cell cultures.
Finally, BON cells harbor a number of untypical mutations (e.g., in TP53, TSC2) [18] that
may drive non-responsiveness of proliferation to regulation by AGTR1 agonists and antagonists.
Similarly, QGP-1 cells are known for a number of mutations that are not typical for well-differentiated
neuroendocrine tumors. This clearly constitutes a limitation of the experimental approach, as does
the fact that it is a pancreatic NEN cell line (BON) that is strongly AGTR1-positive, while, overall,
pancreatic NEN show no significant overexpression. Unfortunately, an AGTR1-overexpressing siNEN
cell line that could be employed in the in vivo imaging experiments was not available. In contrast
to other tumor entities like breast cancer or colorectal cancer with hundreds of cell lines, in the field
of the heterogeneous neuroendocrine neoplasms, comparatively few cell lines have been developed,
and almost none is available in public repositories. These cell lines do not at all recapitulate the
landscape of these tumors. The lack of data for lung NEN is another limitation of this study, which was
focused on NEN in the gastroenteropancreatic system. The scarcity of cell model systems in the field is
currently improving step by step [19], and more novel cell lines may become available with a more
typical tumor biology. Primary cell cultures in 2D or 3D as well as patient-derived xenografts may
pave the way for more appropriate and authentic NEN in vitro and in vivo models.
Radiolabeled AGTR1-targeted peptides and small molecules have been primarily utilized for
cardiac and cardiovascular imaging to date, to select patients for distinct treatment options and to
better predict therapy response [20]. To the best of our knowledge, this is the first study investigating
the applicability of AGTR1-based tumor targeting. Biodistribution of the two different ITCC-labeled
targeted ligands was evaluated in a xenograft mouse model, revealing a significant accumulation
of saralasin–ITCC in receptor-positive BON tumors. The superior performance of saralasin–ITCC
was unexpected, as the introduction of the dye molecule ITCC decreased its affinity 250-fold when
compared to the published Ki value of 1 nM [21]. Although a slow dissociation rate from the receptor is
mostly associated with high affinity binding, both parameters do not necessarily have to correlate [22].
For a translation of this targeting principle into a clinically relevant theranostics approach, the affinity
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of a tracer will have to be improved, e.g., by coupling the chelator to another site in the molecule or by
the introduction of another spacer.
4. Materials and Methods
4.1. Reagents
If not indicated otherwise, chemicals were obtained from Sigma Aldrich (St. Louis, MO, USA).
Gαq inhibitor UBO-QIC was purchased from the Institute of Pharmaceutical Biology, University of
Bonn (Bonn, Germany), AKT-Inhibitor AZD-5363, #A9601, from LKT laboratories (St Paul, MN, USA),
ERK-Inhibitor SCH772984, #B1682-5, from BioVision (Milpitas, CA, USA), and β-arrestin inhibitor
barbadin, #Axon2774, from Axon Medchem (Groningen, The Netherlands).
4.2. Compound Library
The compound library used for screening consisted of the following components:
compounds 1–866 were from the G-Protein Coupled Receptor (GPCR) Peptide Ligand Library
(Phoenix Pharmaceuticals, Burlingame, CA, USA); compounds 867–956 from the Orphan Peptide
Ligand Library (Qventas Labs, Branford, CT, USA), and compounds 957–998 from various sources.
All compounds in the library are listed in Table S1.
4.3. Tissues
This study was carried out in accordance with the recommendations and protocol approval by
the local ethics committee at Charité—Universitätsmedizin Berlin with written informed consent from
all subjects, in accordance with the Declaration of Helsinki. Samples were flash-frozen after surgical
resection and stored at −80 ◦C until further use. Of 42 pancreatic NEN samples, 7 (17%) were grade 1,
27 (64%) were grade 2 and 8 (19%) were grade 3. Seventeen (40%) of the pNENs were from metastatic
samples; 25 (60%) were from primary tumor samples. The mean Ki67 value for the pNENs was 14.24
(95% CI 7.73–20.75). Of 71 small intestinal NEN samples, 38 (53.5%) were grade 1, 32 (45%) were grade 2,
and 1 (1.5%) was grade 3. Twenty-five (35%) of the siNENs were from metastatic samples; 46 (65%)
were from primary tumor samples. The mean Ki67 value for the siNENs was 3.92 (95% CI 2.44–5.39).
4.4. Reverse Transcription Quantitative Real-Time PCR (RT-qPCR)
RNA isolation, reverse transcription and quantitative real-time PCR were performed as previously
described [23]. Oligonucleotide primer sequences are indicated in Table 1. Plotted values were
corrected for different primer efficiencies and normalized on the geometric mean of UBC, HPRT1 and
ALG9 or GAPDH using the ∆∆Ct method [24]. Reference genes were validated and chosen using the
geNorm algorithm [25] by qbase+ software (Biogazelle, Ghent, Belgium).
Table 1. Primer sequences used for RT-qPCR.
Gene Primer forward Sequence Primer Reverse Sequence AmpliconLength (bp)
AGTR1 TTTTCGTGCCGGTTTTCAGC TGCAACTTGACGACTACTGC 100
SSTR2 CCCCTCACCATCATCTGTCT AGGTGAGGACCACCACAAAG 247
UBC ATTTGGGTCGCAGTTCTTG TGCCTTGACATTCTCGATGGT 133
ALG9 GTCTTCTGGCTTTTGTGAGCTG TCACGTGCAACCCAAACTTC 78
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 94
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 87
4.5. AGTR1 Ligands and Ligand Conjugates
Angiotensin II as well as saralasin-ITCC (the dye indotricarbocyanine (ITCC) linked
via 4,7,10-trioxatridecan-succinamic acid (TTDS)) were obtained from peptides&elephants
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(Hennigsdorf, Germany). Valsartan and PD123319 were from Tocris (Bristol, UK). Valsartan–ITCC
(the dye ITCC linked via 1,3-diamino propane) was synthesized as described in the Supplementary
Methods Subsection.
4.6. Other Methods and Data Availability
Further methods are described as part of the Supplementary Material. Numerical data for all
applicable experiments (xlsx file) have been deposited in an open data repository for public access:
http://doi.org/10.5281/zenodo.4009499.
5. Conclusions
The proof of principle for AGTR1-based tumor imaging in this study may pave the way for
a translation into diagnostic approaches like PET imaging and AGTR1-directed peptide receptor
radioligand therapy (PRRT) for NENs employing chelator-based AGTR1 radiotracers.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/11/3138/
s1, Figure S1: Correlation analysis, Figure S2: HPLC purification of radiolabeled angiotensin II, Figure S3:
Quantification of autoradiography by an alternative method, Figure S4: In vitro receptor autoradiography of
pancreatic and small-intestinal NET tissues, Figure S5: In vitro receptor autoradiography of pancreatic and
small-intestinal control tissues, Figure S6: In vivo near-infra red fluorescent (NIRF) imaging with AGTR1-targeting
valsartan–ITCC, Table S1: Screening library compound list, Table S2: Confirmed hits from screening, Table S3:
Clinical characteristics of the tissues analyzed by receptor autoradiography.
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